Galapagos has developed a target discovery platform that provides novel starting points for drug and antibody therapies, thereby addressing the industry's need for innovative, disease-modifying medicines. Galapagos is exploiting this platform in disease areas for which there is a clear need for better medicines. The Company's product portfolio consists mainly of new mode-of-action drugs in bone and joint diseases as well as programs in cancer metastasis, cachexia and orphan diseases. To enable the progression of a broad portfolio of programs, Galapagos has established risk sharing alliances with big pharma companies in specific disease areas. Through an alliance with MorphoSys, Galapagos is also developing new antibody therapies in bone and joint diseases.

Galapagos' service division, which includes BioFocus and the recently acquired service operations from Argenta, offers a full suite of target-to-drug discovery products and services to pharma, biotech and patient foundations - encompassing target and drug discovery through to the delivery of pre-clinical candidates.

August 6, 2010
Galapagos initiates Phase I study for JAK inhibitor GLPG0634, acquires full rights to compound from GSK
Read more

August 6, 2010
Galapagos half year results in line with full year guidance
View webcast presentation
Read more

July 16, 2010
Galapagos and University of Bristol enter drug discovery collaboration in chronic pain
Read more